Compare AAT & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAT | GLUE |
|---|---|---|
| Founded | 1967 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2011 | 2021 |
| Metric | AAT | GLUE |
|---|---|---|
| Price | $18.85 | $24.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $20.00 | ★ $27.00 |
| AVG Volume (30 Days) | 425.1K | ★ 2.4M |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | ★ 7.23% | N/A |
| EPS Growth | ★ 5.06 | N/A |
| EPS | ★ 1.02 | 0.25 |
| Revenue | ★ $435,170,000.00 | $181,538,000.00 |
| Revenue This Year | N/A | $84.02 |
| Revenue Next Year | $4.09 | N/A |
| P/E Ratio | ★ $18.51 | $100.27 |
| Revenue Growth | N/A | ★ 1112.27 |
| 52 Week Low | $16.69 | $3.50 |
| 52 Week High | $25.36 | $25.77 |
| Indicator | AAT | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 71.24 |
| Support Level | $18.31 | $13.69 |
| Resistance Level | $19.21 | $25.77 |
| Average True Range (ATR) | 0.30 | 1.51 |
| MACD | -0.00 | 0.82 |
| Stochastic Oscillator | 61.00 | 87.58 |
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.